zoledronic acid has been researched along with Thalassemias in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bazrafshan, A; Bordbar, M; Bozorgi, H; Haghpanah, S; Saki, F; Zekavat, OR | 1 |
| Alexakos, P; Christoulas, D; Konstantinidou, M; Terpos, E; Tsiftsakis, E; Voskaridou, E | 1 |
| Bilalis, A; Boutsikas, G; Christoulas, D; Kastritis, E; Papatheodorou, A; Terpos, E; Varvagiannis, K; Voskaridou, E; Xirakia, C | 1 |
| Azar, ST; Habr, D; Inati, A; Koussa, S; Mahfouz, RA; Otrock, ZK; Shamseddeen, WA; Taher, AT | 1 |
| Antoniadou, L; Christoulas, D; Terpos, E; Voskaridou, E | 1 |
| Charafeddine, KM; Mahfouz, RA; Otrock, ZK; Rayes, RF; Taher, AT; Zahed, LF | 1 |
4 trial(s) available for zoledronic acid and Thalassemias
| Article | Year |
|---|---|
Comparative effectiveness of alendronate and zoledronic acid on bone mass improvement in transfusion-dependent thalassemia patients.
Topics: Absorptiometry, Photon; Adolescent; Adult; Alendronate; Blood Transfusion; Bone and Bones; Bone Density; Bone Density Conservation Agents; Female; Humans; Male; Middle Aged; Thalassemia; Young Adult; Zoledronic Acid | 2019 |
Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial.
Topics: Adult; Biomarkers; Bone Density; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Osteoporosis; Pain; Thalassemia; Time Factors; Zoledronic Acid | 2008 |
Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial.
Topics: Adolescent; Adult; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Male; Osteogenesis; Osteoporosis; Prospective Studies; Thalassemia; Zoledronic Acid | 2006 |
Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Diphosphonates; Erythropoiesis; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Thalassemia; Zoledronic Acid | 2008 |
2 other study(ies) available for zoledronic acid and Thalassemias
| Article | Year |
|---|---|
Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration.
Topics: Absorptiometry, Photon; Acid Phosphatase; Adult; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; Isoenzymes; Male; Middle Aged; Osteocalcin; Osteopontin; Osteoporosis; Osteoprotegerin; Peptides; Randomized Controlled Trials as Topic; Tartrate-Resistant Acid Phosphatase; Thalassemia; Treatment Outcome; Young Adult; Zoledronic Acid | 2009 |
Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Cohort Studies; Diphosphonates; Genotype; Humans; Imidazoles; Osteoporosis; Polymorphism, Single Nucleotide; Receptors, Calcitriol; Thalassemia; Zoledronic Acid | 2008 |